Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have been diagnosed (clinically) with T1D for at least 1 year or are patients with T2D on basal bolus insulin therapy for at least 6 months
HbA1c ≥8% as confirmed by point-of-care test at screening
Are currently using the Dexcom G6 CGM or agree to start using the Dexcom G6 during the study and agree to switch to Glooko RMA
Are currently using Humalog ® insulin or another rapid acting insulin analogue (e.g., Apidra® , or Novorapid ® ) and agree to switch to study-provided Humalog mealtime insulin for duration of trial
Have been prescribed ≥3 doses of bolus insulin per day
Must be taking a stable insulin dose regimen (per investigator's judgement) for at least 3 months preceding study screening
Have in-home refrigeration for storage of insulin
You may not be if
Previously used the Glooko RMA and/or Dexcom G6 CGM and were judged by the investigator to be non-adherent
Have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed
Have previously used or have been using an approved or investigational connected pen system within the 3 months prior to screening
Are currently breastfeeding, pregnant, or plan to become pregnant during the next 4-6 months
Are on ultra-rapid insulin (e.g., Fiasp or Lyumjev) or rapid acting human insulin (i.e., Humulin) for previous 3 months, at the time of screening
Are currently undergoing dialysis treatment or have any other medical condition which may preclude them from participating in this trial as per the investigator's judgement
Have vision loss or vision impairment that does not allow recognition of Glooko RMA screen features
